Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$132.88 +0.4%	$132.19	$99.71 ▼ $141.23	$231.38B	0.73	6.10 million shs	11.32 million shs
BMY Bristol Myers Squibb	$46.87 +0.1%	$48.20	$39.35 ▼ $63.33	$95.36B	0.38	12.99 million shs	47.28 million shs
NVS Novartis	$115.62 -0.3%	$113.06	$96.06 ▼ $120.92	$244.56B	0.59	1.59 million shs	2.47 million shs
PFE Pfizer	$23.97 +0.4%	$23.26	$20.92 ▼ $31.54	$136.28B	0.57	41.34 million shs	62.63 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	0.00%	-1.87%	+1.08%	+5.32%	+27.79%
BMY Bristol Myers Squibb	0.00%	-5.71%	-0.26%	-23.25%	+14.84%
NVS Novartis	0.00%	-3.12%	+2.82%	+3.13%	+10.18%
PFE Pfizer	0.00%	-2.22%	+4.12%	-8.53%	-12.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.9434 of 5 stars	2.4	5.0	4.2	4.5	3.5	2.5	2.5
BMY Bristol Myers Squibb	4.9487 of 5 stars	3.2	5.0	4.2	4.0	3.5	3.3	1.3
NVS Novartis	1.6962 of 5 stars	1.0	4.0	2.5	0.0	2.3	0.0	1.9
PFE Pfizer	4.8569 of 5 stars	2.3	4.0	4.2	4.3	2.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.76	Moderate Buy	$142.61	7.32% Upside
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.75% Upside
NVS Novartis	2.00	Hold	$123.38	6.71% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	21.69% Upside

Current Analyst Ratings Breakdown

Latest ABT, NVS, PFE, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/17/2025	ABT Abbott Laboratories	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$133.00 ➝ $145.00
4/17/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$132.00 ➝ $142.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.51	$6.58 per share	20.20	$27.62 per share	4.81
BMY Bristol Myers Squibb	$48.30B	1.97	$5.89 per share	7.96	$8.08 per share	5.80
NVS Novartis	$50.32B	4.85	$10.69 per share	10.82	$21.59 per share	5.36
PFE Pfizer	$63.63B	2.14	$4.37 per share	5.49	$15.62 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.71	17.24	23.19	2.53	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.55	7.70	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	18.07	13.12	1.67	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.37	7.91	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)

Latest ABT, NVS, PFE, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.78%	N/A	30.61%	54 Years
BMY Bristol Myers Squibb	$2.48	5.29%	N/A	92.88%	17 Years
NVS Novartis	$2.60	2.25%	N/A	40.63%	N/A
PFE Pfizer	$1.72	7.18%	N/A	124.64%	16 Years

Latest ABT, NVS, PFE, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.26	1.78	1.27
BMY Bristol Myers Squibb	2.65	1.28	1.17
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
BMY Bristol Myers Squibb	76.41%
NVS Novartis	13.12%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
BMY Bristol Myers Squibb	0.07%
NVS Novartis	0.01%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

ABT, NVS, PFE, and BMY Headlines

Recent News About These Companies

Cambridge Investment Research Advisors Inc. Acquires 64,277 Shares of Pfizer Inc. (NYSE:PFE)

June 22 at 7:25 AM | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Has $4.18 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 22 at 6:20 AM | marketbeat.com

Heartland Bank & Trust Co Buys New Shares in Pfizer Inc. (NYSE:PFE)

June 22 at 5:30 AM | marketbeat.com

Matrix Asset Advisors Inc. NY Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 22 at 5:13 AM | marketbeat.com

Center For Asset Management LLC Reduces Stake in Pfizer Inc. (NYSE:PFE)

June 21 at 7:21 AM | marketbeat.com

Woodmont Investment Counsel LLC Acquires 16,987 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 7:00 AM | marketbeat.com

Monte Financial Group LLC Purchases 43,740 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 6:50 AM | marketbeat.com

World Equity Group Inc. Sells 38,707 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 6:25 AM | marketbeat.com

PFG Investments LLC Grows Position in Pfizer Inc. (NYSE:PFE)

June 21 at 5:50 AM | marketbeat.com

Advocate Group LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

June 21 at 5:50 AM | marketbeat.com

Advisor Resource Council Invests $1.55 Million in Pfizer Inc. (NYSE:PFE)

June 21 at 5:21 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Reduced by United Advisor Group LLC

June 21 at 4:39 AM | marketbeat.com

Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging

June 20 at 2:24 PM | finance.yahoo.com

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

June 20 at 11:06 AM | zacks.com

June 20 at 10:00 AM | zacks.com

Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out

June 20 at 9:06 AM | seekingalpha.com

Private Wealth Partners LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 7:36 AM | marketbeat.com

Cantor Fitzgerald Investment Advisors L.P. Sells 14,500 Shares of Pfizer Inc. (NYSE:PFE)

June 20 at 7:26 AM | marketbeat.com

Good Steward Wealth Advisors LLC Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 6:33 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Means Investment CO. Inc.

June 20 at 5:48 AM | marketbeat.com

Pfizer: An Offensive Play For A Bear Market

June 20 at 5:20 AM | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABT, NVS, PFE, and BMY Company Descriptions

Abbott Laboratories NYSE:ABT

$132.88 +0.47 (+0.36%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$133.12 +0.23 (+0.17%)

As of 06/20/2025 07:30 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$46.87 +0.03 (+0.06%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$46.93 +0.06 (+0.13%)

As of 06/20/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Novartis NYSE:NVS

$115.62 -0.34 (-0.29%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$116.65 +1.03 (+0.89%)

As of 06/20/2025 07:42 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$23.97 +0.09 (+0.37%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$23.99 +0.02 (+0.09%)

As of 06/20/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time